21.8 C
Washington

Lilly to build $2.5 billion Germany plant as obesity drug demand soars | Reuters News Agency

Date:

Share:

DealsHealth

Reuters exclusively reported that Eli Lilly (LLY.N) will build its first plant in Germany in the western town of Alzey for 2.3 billion euros ($2.5 billion), the U.S. drugmaker said on Friday, as the sector scrambles to meet soaring demand for new diabetes and obesity therapies. 

Market Impact

As the sector scrambles to meet demand for new diabetes and obesity therapies, the investment, confirmed by Lilly on Nov 17, will contribute to meeting surging demand for weight-loss drug Mounjaro from 2027. Eli Lilly and Danish rival Novo Nordisk (NOVOb.CO) are leading a race to seize an estimated $100 billion future global market for anti-obesity treatments.   

Article Tags

Topics of Interest: DealsHealth

Type: Reuters Best

Sectors: Pharmaceuticals & HealthcareRetail & Consumer Goods

Regions: Europe

Countries: Germany

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Important Regional Story

Source link

Subscribe to our magazine

━ more like this

California offering $25 gift cards to encourage bird flu testing

The Centers for Disease Control and Prevention is now working with California on a project that is offering gift cards...

At the American Museum of Natural History, a Look to Outer Space

This article is part of our Museums special section about how artists and institutions are adapting to changing times.What if you could stand in...

Real ID deadline is weeks away and most states aren’t fully compliant yet

In less than a month, Americans and permanent residents will only be able to pass through airport security or enter...